Top Page
QHSLab
(OTC:USAQ)
QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)
QHSLab Business Overview & Revenue Model
QHSLab Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.61M | 2.13M | 1.41M | 1.24M | 1.41M | 124.53K |
| Gross Profit | 1.73M | 1.36M | 793.61K | 619.52K | 670.75K | 50.09K |
| EBITDA | 278.24K | 352.39K | -91.29K | -434.60K | -487.63K | -296.40K |
| Net Income | -386.75K | -259.24K | -468.36K | -996.00K | -770.18K | -327.39K |
Balance Sheet | ||||||
| Total Assets | 1.73M | 1.80M | 1.68M | 1.96M | 2.21M | 297.86K |
| Cash, Cash Equivalents and Short-Term Investments | 158.39K | 157.17K | 51.58K | 178.69K | 286.86K | 94.34K |
| Total Debt | 1.21M | 1.72M | 1.78M | 1.68M | 1.30M | 631.00K |
| Total Liabilities | 2.35M | 2.41M | 2.06M | 1.88M | 1.38M | 906.19K |
| Stockholders Equity | -610.91K | -607.76K | -375.62K | 76.25K | 824.07K | -608.33K |
Cash Flow | ||||||
| Free Cash Flow | 135.13K | 142.44K | -159.63K | -388.11K | -509.31K | -197.26K |
| Operating Cash Flow | 135.13K | 142.44K | -159.63K | -350.99K | -354.74K | -165.56K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -37.12K | -154.57K | -31.70K |
| Financing Cash Flow | -72.69K | -36.85K | 32.52K | 279.95K | 701.82K | 268.02K |
QHSLab Technical Analysis
QHSLab Risk Analysis
QHSLab Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $8.29M | 16.04 | ― | ― | 43.55% | -461.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.92M | 1.50 | -467.14% | ― | -8.93% | 97.80% | |
44 Neutral | $2.33M | -0.28 | -191.39% | ― | ― | 76.53% | |
42 Neutral | $2.59M | -3.70 | -173.74% | ― | 82.96% | 82.04% | |
41 Neutral | $706.47K | -0.05 | -854.61% | ― | -12.39% | 44.61% |
QHSLab Corporate Events
On January 26, 2026, QHSLab reported preliminary unaudited financial results for 2025 showing revenue rose just over 25% to $2.68 million and gross profit increased more than 32% to $1.80 million, with gross margins improving from about 64% to roughly 67% despite operating with a lean cost structure. During the fourth quarter of 2025, the company executed a major balance-sheet cleanup by reducing outstanding convertible debt and accrued interest from approximately $2.0 million to about $20,000, which is expected to cut annual interest expense by more than $200,000 and free up cash for product development, sales, and platform expansion; management also highlighted early reimbursement activity from its Q-Cog cognitive and behavioral screening solution and growing momentum in its Integrated Service Program client base as positioning QHSLab for continued progress in 2026, with final audited 2025 results to follow in its forthcoming annual report.
The most recent analyst rating on (USAQ) stock is a Hold with a $0.94 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.
QHSLab, Inc. entered into a Note Repurchase Agreement with MedScience Research Group, Inc. under which it repurchased, cancelled, and extinguished a promissory note originally issued on June 23, 2021, that had an outstanding principal and accrued interest balance of $470,529 as of December 31, 2025. In exchange, the company issued 1,568,432 shares of common stock in a private, non-cash transaction exempt from registration under U.S. securities laws, thereby fully satisfying the debt and eliminating a related-party obligation involving its CEO’s minority shareholding and service relationship with MedScience; the company stated that this move simplifies its capital structure, removes related-party debt, and is expected to improve the clarity of its balance sheet and financial reporting.
The most recent analyst rating on (USAQ) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.
On January 16, 2026, QHSLab announced that it has begun a formal process to expand its board of directors by adding independent members, aiming to strengthen corporate governance, enhance oversight, and support future capital markets objectives, including potential uplisting. The move follows recent steps to simplify the company’s capital structure, including the substantial elimination of legacy convertible debt, reduced interest expense, and completion of a funding transaction designed to support growth while limiting dilution, positioning QHSLab with a stronger balance sheet and governance framework more closely aligned with shareholder interests and the standards of larger public companies.
The most recent analyst rating on (USAQ) stock is a Buy with a $0.84 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.
On January 6, 2026, QHSLab issued an unaudited financial and operational update ahead of an investor session, reporting that revenue for the nine months ended September 30, 2025 rose 32% year over year to $1.99 million, with gross profit of $1.32 million at a 66% margin, net operating income before interest of $95,738, and approximately $630,000 in cash as of December 31, 2025. During the fourth quarter of 2025, the company nearly eliminated its outstanding convertible debt, cutting it from about $1.4 million to $20,000 and thereby significantly reducing interest expense, while management indicated the business exited 2025 in a cash-flow-positive operating position and highlighted a capital structure consisting of 13.4 million shares outstanding, a relatively small public float, and a sizable block of restricted shares from recent financings and debt conversions.
The most recent analyst rating on (USAQ) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.
On December 31, 2025, QHSLab, Inc. entered into a Promissory Note Modification and Partial Conversion Agreement with creditor Alex Mirakian MD PA, under which $126,548 of a previously issued convertible note’s principal and accrued interest was converted into 421,827 shares of QHSLab common stock at $0.30 per share, leaving $20,000 outstanding. The company extended the maturity date of the remaining balance to December 31, 2026, kept the original conversion features on the residual debt, and preserved the right to prepay without penalty, while issuing the new shares in a private, exempt transaction that reduces debt but dilutes existing shareholders and modestly strengthens QHSLab’s balance sheet.
The most recent analyst rating on (USAQ) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on QHSLab stock, see the USAQ Stock Forecast page.
On December 26, 2025, QHSLab raised approximately $500,000 in a private placement of common stock and warrants to two accredited investors, issuing about 1.67 million shares at $0.30 per share and 416,666 warrants exercisable at $0.60 through 2030, with net proceeds of more than $495,000 earmarked for general corporate purposes and working capital. Announced publicly on December 29, 2025, the financing followed the November 2025 repurchase and retirement of more than $1.4 million in high-cost legacy convertible notes, eliminating several million shares of potential dilution and over $200,000 in annual interest expense; together, the debt retirement and new equity capital materially improve QHSLab’s liquidity and capital structure, allowing management to shift focus toward scaling its digital health offerings, expanding its physician client base and driving recurring revenue growth, against a backdrop of 32% year-over-year revenue growth and a 66% gross margin for the first nine months of 2025.
On December 3, 2025, QHSLab announced the launch of Q-Cog™, a cloud-based cognitive assessment tool designed to aid primary care providers in the early detection of Mild Cognitive Impairment and dementia. The tool combines cognitive, behavioral, and functional screening within a digital workflow, aligning with CMS guidelines and supporting value-based care. In a pilot study, Q-Cog™ identified 54% of 168 patients aged 65 and older as high-risk for cognitive impairment, highlighting the tool’s potential to fill a critical gap in early dementia detection and create new revenue opportunities for QHSLab and its partners.
QHSLab, Inc. released its December 2025 Corporate Presentation on December 1, 2025, detailing its business and operations. The presentation, furnished under Regulation FD, emphasizes the company’s commitment to transparency and the use of various platforms for public information dissemination, highlighting its strategic approach to investor relations and stakeholder engagement.
QHSLab, Inc. reported a transformational year in 2025, marked by significant revenue growth and a strengthened balance sheet, as highlighted in their recent shareholder letter. The company achieved $1.99 million in revenue for the first nine months of 2025, a notable increase from the previous year, and eliminated a major source of dilution by retiring convertible notes. This strategic move removed over $1.4 million in liabilities and protected shareholders from potential market dilution, positioning QHSLab for strong growth in 2026 with a focus on expanding digital health revenues and enhancing operational efficiency.
On November 18, 2025, QHSLab, Inc. completed a Note Repurchase Agreement to retire over $1.4 million in defaulted convertible debt, originally issued in 2021 and 2022, for a cash payment of $300,000. This strategic move strengthens QHSLab’s balance sheet, reduces future dilution risks, and eliminates conversion rights, positioning the company for healthier financial growth. The company reported a 35% increase in Q3 2025 revenue, reflecting strong operational momentum and effective technology deployment in primary care settings.